Mivtachim The Workers Social Insurance Fund’s Insight Molecular Diagnostics IMDX Stock Holding History

Mivtachim The Workers Social Insurance Fund’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-29	Closed	-$4K	–	16
2016 Q4	$4K	Hold	29	–	–	﹤0.01%	18
2016 Q3	$3K	Hold	29	–	–	﹤0.01%	21
2016 Q2	$2K	Hold	29	–	–	﹤0.01%	22
2016 Q1	$3K	Buy	+29	New	+$2.57K	﹤0.01%	29

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Family Management New York $834M AUM 20.83% 1-Year Est. Return

Mivtachim The Workers Social Insurance Fund's IMDX Position: Q1 2017 in Review

Mivtachim The Workers Social Insurance Fund sold out of Insight Molecular Diagnostics (IMDX) in Q1 2017, closing a stake of 29 shares — an estimated $4K sold.

Mivtachim The Workers Social Insurance Fund first reported a position in IMDX in Q1 2016 and held it in 4 quarters. The position peaked at $4K in Q4 2016. 33 funds tracked by Wall St. Rank hold IMDX as of Q1 2017.

Mivtachim The Workers Social Insurance Fund reported no remaining Insight Molecular Diagnostics position as of Q1 2017 after selling out during the quarter.
Mivtachim The Workers Social Insurance Fund sold 29 Insight Molecular Diagnostics shares in Q1 2017, an estimated $4K.
Mivtachim The Workers Social Insurance Fund first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 4 quarters.
Mivtachim The Workers Social Insurance Fund's Insight Molecular Diagnostics position peaked at $4K in Q4 2016.
33 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2017.

Based on Mivtachim The Workers Social Insurance Fund's 13F filing for Q1 2017, filed 30 May 2017.